BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Wang C, Wang S, Zhou Q, Dai D, Shi J, Xu X, Luo Q. Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. Front Pharmacol 2020;11:53. [PMID: 32116727 DOI: 10.3389/fphar.2020.00053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Lu B, Yue P, Shao Q, Mao L, Qiao H. Fertility and early embryonic development toxicity and toxicokinetic study of KFP‐H008 in Sprague–Dawley rats. Birth Defects Research. [DOI: 10.1002/bdr2.2002] [Reference Citation Analysis]
2 Shi Y, Meng D, Wang S, Geng P, Xu T, Zhou Q, Zhou Y, Li W, Chen X. Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats. Drug Des Devel Ther 2021;15:3661-73. [PMID: 34456561 DOI: 10.2147/DDDT.S323186] [Reference Citation Analysis]
3 Hwang S, Ko JW, Lee H, Kim S, Kim B, Song GS, Kim J. Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects. Front Pharmacol 2021;12:754849. [PMID: 34867368 DOI: 10.3389/fphar.2021.754849] [Reference Citation Analysis]
4 Chen F, Jiang H, Xu J, Wang S, Meng D, Geng P, Dai D, Zhou Q, Zhou Y. In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine. Drug Des Devel Ther 2020;14:4815-24. [PMID: 33204067 DOI: 10.2147/DDDT.S276704] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Wang J, Chen F, Jiang H, Xu J, Meng D, Geng P, Dai D, Hu J, Zhou Y, Zhou Q, Wang S. Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. Front Pharmacol 2020;11:593518. [PMID: 33746741 DOI: 10.3389/fphar.2020.593518] [Reference Citation Analysis]
6 Wu Y, Li M, Guo Y, Liu T, Zhong L, Huang C, Ye C, Liu Q, Ren Z, Wang Y. The Effects of AT-533 and AT-533 gel on Liver Cytochrome P450 Enzymes in Rats. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35137361 DOI: 10.1007/s13318-022-00757-w] [Reference Citation Analysis]
7 Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021;26:e12788. [PMID: 33580612 DOI: 10.1111/hel.12788] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 34550866 DOI: 10.1080/17474124.2021.1984878] [Reference Citation Analysis]
9 Belinskaia DA, Voronina PA, Shmurak VI, Vovk MA, Batalova AA, Jenkins RO, Goncharov NV. The Universal Soldier: Enzymatic and Non-Enzymatic Antioxidant Functions of Serum Albumin. Antioxidants (Basel) 2020;9:E966. [PMID: 33050223 DOI: 10.3390/antiox9100966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]